This sublease is a routine facilities arrangement with no material financial impact. Monitor the next 10-Q for any disclosed rent obligations, but no immediate trading catalyst.
Price Chart
Executive Summary
First Tracks Biotherapeutics entered into a 12-month sublease agreement with AnaptysBio for approximately 45,057 square feet of office/lab space in San Diego, effective June 15, 2026. The company has an option to extend the term and a right to early terminate with three months' notice. This is a routine real estate transaction with no material financial terms disclosed, providing operational flexibility but no direct impact on revenue or earnings.
Key Facts
- Sublease of ~45,057 rentable square feet at 10770 Wateridge Circle, San Diego, CA
- Initial term of 12 months from June 15, 2026
- Option to extend until earlier of April 4, 2028 or 12 months from renewal start
- Right to terminate at any time with at least 3 months' notice
- Rent equals monthly Basic Rent plus Additional Rent under the Master Lease (amounts not disclosed)
- Sublease is subordinate to the Master Lease with AnaptysBio
Financial Impact
No financial terms disclosed; rent equals pass-through of master lease obligations
Risk Factors
- If AnaptysBio's Master Lease terminates, the sublease immediately ends
- Undisclosed rent amounts could be material if the company is cash-constrained
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277504 |
| Document: 0001193125-26-277504-index-headers.html | 0001193125-26-277504 |
| Document: 0001193125-26-277504-index.html | 0001193125-26-277504 |
| Document: 0001193125-26-277504.txt | 0001193125-26-277504 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers